QL1206

DRUG5 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

Bone MetastasesHealthy PeoplePostmenopausal OsteoporosisPostmenopausal Women With Osteoporosis at High Risk of Fracture

Phase 1

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

CompletedNCT03651947

Qilu Pharmaceutical Co., Ltd.Healthy People

Start: 2018-08-20End: 2019-05-22Updated: 2019-10-16

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults

Qilu Pharmaceutical Co., Ltd.Healthy People

Start: 2019-10-31End: 2020-10-31Target: 144Updated: 2019-12-30

Phase 3

Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk

Qilu Pharmaceutical Co., Ltd.Postmenopausal Osteoporosis

Start: 2019-06-05End: 2021-12-01Target: 440Updated: 2019-11-06

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Qilu Pharmaceutical Co., Ltd.Bone Metastases

Start: 2019-04-26End: 2022-06-10Target: 700Updated: 2020-09-22

A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®

RecruitingNCT07062978

Qilu Pharmaceutical Co., Ltd.Postmenopausal Women With Osteoporosis at High Risk of Fracture

Start: 2025-06-27End: 2027-01-31Target: 278Updated: 2025-07-14

Related Papers

Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: A subgroup analysis of a randomized, double-blinded phase III study.

2025-06-01

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial

BioDrugs2023-02-2111 citations

A multicenter, randomized, double-blind, phase III trial comparing denosumab biosimilar QL1206 and denosumab in patients with bone metastases from solid tumors.

Journal of Clinical Oncology2022-06-01